cefotaximase and ampc-producing shigella flexneri in case of dysentery from southern india
Clicks: 208
ID: 170441
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
208 views
18 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #54 of 129 articles by views in bjog : an international journal of obstetrics and gynaecology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 129 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Diarrhoea and dysentery caused by Shigella spp. are major public health concerns. Emerging multidrug resistance (MDR) in this pathogen further complicates this disease. Extended spectrum β-lactamases (ESBLs) have been described in this pathogen, which significantly compromises the treatment options for shigellosis. The usual ESBLs seen are sulfhydryl variable (SHV)-type; cefotaximases (CTX-M) are very uncommonly detected. Here, we report a CTX-M type and AmpC-producing Shigella flexneri from a three-year-old boy residing in Central Kerala, South India.
| Reference Key |
oommen2013indiancefotaximase
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;S Oommen;P M Sivan Pillai;S Sushamabai;P Jose Paul |
| Journal | bjog : an international journal of obstetrics and gynaecology |
| Year | 2013 |
| DOI |
10.4103/0255-0857.108734
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.